Myriad Genetics shareholders approve equity plan increase and charter amendments at 2023 annual meeting

On June 1, 2023, the Company's stockholders voted at the Annual Meeting to approve an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Restated Certificate of Incorporation") to limit the personal liability of certain senior officers of the Company as permitted by recent amendments to Delaware law (the "Officer Exculpation Amendment").

The Company's stockholders also voted at the Annual Meeting to approve an amendment to the Restated Certificate of Incorporation to add a federal forum selection clause for claims under the Securities Act of 1933, as amended (the "Federal Forum Selection Clause Amendment" and together with the Officer Exculpation Amendment, the "Amendments").

Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 68,121,537 2,731,973 36,771 3,608,837 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.

Proposal No. 7: To Approve an Amendment to the Company's Restated Certificate of Incorporation to Limit Personal Liability of Certain Senior Officers of the Company Votes Votes Votes Broker For Against Abstained Non-Votes 59,118,369 11,652,693 119,219 3,608,837 The stockholders voted to approve the Officer Exculpation Amendment.

Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 Votes Votes Votes For Against Abstained 71,921,900 2,563,981 13,237 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved by stockholders.

Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes Paul M. Bisaro 70,549,855 311,078 29,348 3,608,837 Rashmi Kumar 69,479,076 1,382,472 28,733 3,608,837 Lee N. Newcomer, M.D. 70,034,002 839,343 16,936 3,608,837 Each of Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D., was elected to serve as a director of the Company for a term expiring at the 2026 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.

Proposal No. 4: Advisory Vote on the Frequency of Holding an Advisory Vote on the Compensation of Our Named Executive Officers Votes Votes Votes Votes Every One Year Every Two Years Every Three Years Abstained 67,953,555 8,982 2,912,353 15,391 The stockholders voted to approve, on an advisory basis, one year as the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.

Proposal No. 6: To Approve an Amendment to the Company's Restated Certificate of Incorporation to Add a Federal Forum Selection Clause Votes Votes Votes Broker For Against Abstained Non-Votes 64,586,633 6,222,162 81,486 3,608,837 The stockholders voted to approve the Federal Forum Selection Clause Amendment.

Proposal No. 5: Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants Votes Votes Votes Broker For Against Abstained Non-Votes 66,996,613 3,829,841 63,827 3,608,837 The stockholders voted to approve the proposed amendment to the 2017 Plan to increase the aggregate number of shares of common stock available for the grant of awards under the 2017 Plan by an additional 4.8 million shares.